Abzena, a Global Partner Research Organization for integrated bench to patient solutions for biologics and bioconjugates, and BioXpress Therapeutics, a world-class leading developer of high quality, monoclonal antibody (mAb) biosimilar therapeutics have announced their partnership to support biosimilar development for third party customers. The partnership creates an integrated solution between two leading service providers with expertise in biosimilar development and GMP manufacture.
The partnership will ensure biosimilar drug developers benefit from an integrated approach to biosimilars spanning the range from design consultancy, cell line and process development, through to clinical and commercial GMP manufacture. Through access to unrivalled scientific expertise, analytical know-how, and a proven track record for delivering biosimilars, this partnership creates an integrated solution for biosimilar drug developers.
Jonathan Goldman, MD, CEO of Abzena said “We are delighted to enter a partnership with a company who share our commitment to producing biologics to positively impact patient lives particularly those who will benefit from access to lower cost biotherapeutics. This new integrated offering will provide our partners a de-risked approach to biosimilar development, all the way to clinical development and ultimately to the market.”
Gerrit Hagens, PhD, Director at BioXpress Therapeutics commented “This partnership allows for a simplification of drug development timelines for the biosimilars market. The BioXpress Therapeutics and Abzena strengths are complementary and this partnership provides a flexible and innovative approach from small scale biosimilar development through to large scale manufacturing.”